Background {#Sec1}
==========

Bacteremia is characterized by the abnormal presence of bacteria in the bloodstream and can lead to severe complications for the patient as sepsis. This life-threatening condition causes severe organ injuries due to the body's immune response to the infection \[[@CR1]\]. Sepsis furthermore increases morbidity and mortality rates with long-term hospitalizations mainly in intensive care unit (ICU) \[[@CR2]\] and the urgent instauration of a broad-spectrum antimicrobial treatment is mandatory to guarantee the patient's best outcome \[[@CR3], [@CR4]\]. However, rapid tailoring of the empirical antibiotherapy with a targeted antimicrobial therapy is subsequently recommended as it can avoid the emergence of multi-resistant bacteria, a major worldwide public health problem of the twenty-first century \[[@CR5]\].

Identification and antimicrobial susceptibility testing (AST) of the causative agent has to be considered as an important matter of bacteremia management. Until recently, identification and AST were performed from the subculture of a positive blood culture bottle requiring a turnaround time (TAT) to results of 24--48 h \[[@CR6]\]. This delay is now reduced through new genotypic and phenotypic technologies performing the tests directly on the blood of the positive blood culture bottle. For example direct identification with matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF MS) has been extensively validated with successful identification performances beyond 80% \[[@CR7], [@CR8]\]. Complementary molecular-based methods also entered the market offering fast identification combined to the detection of specific resistance genes and requiring a very limited hands-on time yet requiring costly reagents \[[@CR9]\]. Considering speeded-up AST testing, many clinical laboratories have now implemented phenotypic AST by direct inoculation using automated platforms enabling results the day after positivity detection \[[@CR10]\]. Systems enabling AST results on the day of positive blood culture are just very recently available and stand out with their innovative analysis approaches either based on morphokinetic analysis or on light scattering measurements of the bacteria in the presence of the tested antibiotics \[[@CR11], [@CR12]\].

In this study we evaluated the latter approach on the CE-marked automated Alfred 60^AST^ instrument (Alifax, Polverara, PD, Italy). We tested customized panels of antibiotics on all routine positive-detected blood cultures over a 6-month period in comparison with direct automated AST testing. This study aimed at demonstrating acceptable microbiological performances with the Alfred 60^AST^ approach and a reduced TAT compared to routine testing.

Methods {#Sec2}
=======

The study was conducted at the microbiology laboratory of the Cliniques universitaires Saint-Luc -- UCL (CUSL), a 979-bed tertiary hospital in Brussels, Belgium. On average 35.000 blood culture pairs are sampled annually with a 3.7% positivity rate. Blood specimens from patients with a suspected bloodstream infection are inoculated into blood culture bottles (BD Bactec Plus Aerobic and Lytic Anaerobic medium, Becton Dickinson, Franklin Lanes, NJ, USA) and incubated 24 h a day, 7 days a week in a Bactec FX device (BD Diagnostic Systems, Sparks, MD, USA). Standard management of positive blood cultures is performed during laboratory working hours (i.e 8 AM -- 0 AM, 7 days per week) and includes immediate Gram stain, MALDI-TOF MS identification and automated (Phoenix, Becton Dickinson, Franklin Lakes, NJ, USA) AST.

During 2 non-consecutive 3-month periods (February to April 2018 and October to December 2018) all blood cultures detected positive in the 0 AM -10 AM time frame were considered for study inclusion as described in Fig. [1](#Fig1){ref-type="fig"}. Gram stain results allowed the inclusion of positive blood cultures with the single presence of Gram-positive cocci or Gram-negative bacilli. Only the first bottle of each positive blood culture episode was used for testing. Each included blood culture was then processed 1) for plating and a 5-h incubation followed by MALDI-TOF MS identification from the young subculture 2) for automated AST directly from the blood with Phoenix and 3) for automated AST directly from the blood with Alfred 60^AST^. Fig. 1Study inclusion workflow of all blood culture bottles detected positive between 0 AM and 10 AM. AST: antimicrobial susceptibility testing, GPB: Gram-positive bacilli, GPC: Gram-positive cocci, GNB: Gram-negative bacilli, GNC: Gram-negative cocci, ID: identification, MALDI-TOF MS: matrix-assisted laser desorption ionization time-of-flight mass spectrometry

Direct AST of bacteria using Phoenix {#Sec3}
------------------------------------

The automated Phoenix system was routinely used at the CUSL microbiology laboratory to assess antimicrobial susceptibility. AST was performed directly from blood of the positive blood culture. Briefly, an 8 ml aspirate of blood from a positive bottle was injected in a Serum Separator Tube (BD Diagnostic Systems, Sparks, MD, USA) and centrifuged at 2000 rpm for 10 min. After removing the supernatant, bacteria on the surface of the gel were suspended into a Phoenix system ID broth tube and put on the BD Phoenix Autoprep instrument to reach a 0.5 McFarland. Ultimately the suspension was inoculated into the appropriate Phoenix panel (NMIC-408 (product no. 448877, BD) for Gram-negative bacilli, PMIC-90 (product no. 448439, BD) for Gram-positive cocci) and incubated in the Phoenix system following the manufacturers' recommendations.

AST with Alfred 60^AST^ {#Sec4}
-----------------------

Antimicrobials tested with the Alfred 60^AST^ approach were chosen from the CE-approved Alifax antibiotic reagent list after discussion with the hospital antimicrobial stewardship team and in concordance with our local resistance epidemiology. Ultimately we established a "Gram-negative bacilli" and a "Gram-positive cocci" panel comprising a selection of EUCAST lyophilized antibiotics. All antibiotics of the selected panel were tested for each included positive blood culture. However upon identification (same-day MALDI-TOF MS testing on young subculture) availability, result performance analysis was exclusively done on the antibiotics interpretable with EUCAST for the identified strain as presented in Table [1](#Tab1){ref-type="table"}. The manufacturer modified the composition of the cefuroxime and piperacillin-tazobactam Enterobacteriaceae (EB) reagents between the 2 study periods. Table 1Selected antibiotics for result performance analysis following MALDI-TOF MS identification resultMALDI-TOF MS identification resultCustomized panelsTested antibioticsEnterobacteriaceae*Pseudomonas*\
*aeruginosaStaphylococcus*\
*aureus*Coagulase-negative\
StaphylococciEnterococciGram-negative bacillicefuroxime/EU^a^Xceftazidime EB/EUXpiperacillin-tazobactam EB/EUXceftazidime *Pseudomonas*/EUXciprofloxacin/EUXXGram-positive coccicefoxitin *S. aureus*/EUXcefoxitin CNS/EUXampicillin Enterococci/EUX*CNS* coagulase-negative Staphylococci, *EB* Enterobacteriaceae, *EU* EUCAST lyophilized antibiotics, *MALDI-TOF MS* matrix-assisted laser desorption ionization time-of-flight mass spectrometry^a^Cefuroxime results were not taken into account for AmpC-producing Enterobacteriaceae

Briefly, 10 μl blood of a positive bottle was transferred into a 3 ml enrichment broth vial (Alifax) and loaded in the 37 °C area of the Alfred 60^AST^ instrument with a hands-on time of approximately 15 min for 5 samples. First bacterial growth was monitored through turbidity readings every 5 min and once the suspension had reached a 0.4--0.6 McFarland, it was transferred to an empty vial in the refrigerated zone. Then, 100 μl of the bacterial suspension and 200 μl of each antibiotic from the selected panel were loaded into vials containing a 2 ml enrichment broth (Alifax) for AST analysis in the 37 °C area. One vial containing exclusively the bacterial suspension was used as reference vial. The Alfred 60^AST^ system translated light scattering measurements over time of all vials into growth curves and compared with curves from the reference vial. When resistant bacteria continued to grow, turbidity and light scattering increased; conversely, turbidity remained low and light scattering was reduced when bacteria were susceptible to the tested antibiotic.

TAT {#Sec5}
---

TAT measurements started when the sample was loaded on Alfred 60^AST^ or on the Phoenix system and stopped when all AST results were made available by the respective system.

Total TAT to results with Alfred 60^AST^ added up a varying TAT to reach a 0.4--0.6 McFarland suspension and a fixed TAT to AST results requiring a 3 h-analysis for all evaluated antibiotics with the exception of cefuroxime, piperacillin-tazobactam Enterobacteriaceae and ceftazidime *Pseudomonas* requiring a 5-h analysis.

Data analysis {#Sec6}
-------------

Direct Phoenix testing performed from blood of the positive blood cultures was considered as the reference method to evaluate the microbiological performances of the Alfred 60^AST^ instrument with the selected antibiotic reagents applying the EUCAST 6.0 breakpoints (2016). In case of discrepancy, results were verified by disk diffusion using filter paper disks (Bio-Rad, Marnes-la-Coquette, France) and by minimal inhibition concentration measures using E-test (bioMérieux, Marcy l'Étoile, France) from subcultured colonies. Discordances with cefoxitin antibiotics were verified with an in-house PCR for the detection of the *mecA* gene \[[@CR13]\]. Molecular testing was performed on all third-generation cephalosporin-resistant Enterobacteriaceae for the detection of extended-spectrum β-lactamases (ESBL) and of carbapenemases \[[@CR14]\].

Alfred 60^AST^ verifications were performed in accordance with the Cumitech recommendations for the verification and validation of procedures in the clinical microbiology laboratory \[[@CR15]\]. AST result comparison between Alfred 60^AST^ and the reference method was expressed in a categorical agreement percentage (CA) (total categorical matches / total antibiotics tested × 100). Discordances were classified into very major errors (VME: false susceptibility with the evaluated test), major errors (ME: false resistance with the evaluated test) and minor errors (mE: reference test result intermediate and evaluated test sensitive or resistant, or vice versa).

The VME rate was calculated by dividing the number of VME by the number of resistant bacteria (reference method) × 100. The ME rate was calculated by dividing the number of ME by the number of susceptible bacteria (reference method) × 100, while the mE rate was calculated by dividing the number of mE by the total number of strains tested × 100. Acceptable performance rates for CA should be ≥90%, whereas acceptable performance for the VME rate should be ≤3%. The ME rate should be ≤3%. For ME and mE combined, the error rate should be combined ≤7%.

Results {#Sec7}
=======

Sample description {#Sec8}
------------------

During the 2 non-consecutive 3-month periods, 288 positive blood culture bottles were included based on Gram stain results and were composed of 170 Gram-negative bacilli and 118 Gram-positive cocci. AST results of 13 (4.5%) strains were excluded from Alfred 60^AST^ performances evaluation because the antibiotic panels were not validated for their interpretation. Concerned strains were 5 streptococci (1 *Streptococcus salivarius* Group, 3 *Streptococcus mitis* Group and 1 *Streptococcus anginosus* Group), 2 *Fusobacterium periodonticum*, 1 *Micrococcus luteus*, 1 *Bacteroides fragilis*, 1 *Parvimonas micra*, 1 *Haemophilus sputorum*, 1 *Facklamia hominis* and 1 *Peptoniphilus*. Ultimately, the studied population included 166 Gram-negative bacilli and 109 Gram-positive cocci as detailed in Fig. [2](#Fig2){ref-type="fig"}a and b. With regards to the main multi-resistance profiles, 25/155 (16%) Enterobacteriaceae were ESBL-producers (17 CTX-M1, 6 CTX-M9, 1 TEM and 1 SHV), 1/11 (9%) *P. aeruginosa* expressed a VIM-carbapenemase and 3/39 (7.7%) *S. aureus* were methicillin-resistant strains. In total, 570 and 109 antibiotics were evaluated with the Alfred 60^AST^ instrument for respectively Gram-negative and Gram-positive strains. Fig. 2Distribution of the 275 positive blood cultures for the Gram-negative (**a**) and Gram-positive (**b**) strains

Direct AST for gram-negative bacilli -- period I {#Sec9}
------------------------------------------------

During the first study period, AST was performed by both direct Phoenix and Alfred 60^AST^ on 70 Enterobacteriaceae and 5 *P. aeruginosa*. Results comparison led to 89.5% (248/277) CA, 8.7% (6/69) VME, 3.6% (7/197) ME and 7.5% (16/212) mE rates as detailed in Table [2](#Tab2){ref-type="table"}. VME rates exclusively concerned cefuroxime and piperacillin-tazobactam EB respectively 19% (4/21) and 15.4% (2/13). ME rates concerned ceftazidime EB, piperacillin-tazobactam EB and ceftazidime PA (*Pseudomonas*) respectively 4.3% (2/46), 7.8% (4/51) and 20% (1/5). Ciprofloxacin showed a nearly optimal CA of 98.7% (74/75). Table 2AST results with Alfred 60^AST^ compared to direct Phoenix for Gram-negative bacteria during Period IAntibioticCategorical agreement (%)Very major errors (%)Major errors (%)Minor errors (%)Cefuroxime56/60 (93.3)4/21 (19)0/39NACeftazidime EB58/68 (85.3)0/162/46 (4.3)8/68 (11.8)Piperacillin-tazobactam EB56/69 (81.2)2/13 (15.4)4/51 (7.8)7/69 (10.1)Ceftazidime PA4/5 (80)0/01/5 (20)NACiprofloxacin74/75 (98.7)0/190/561/75 (1.3)Total248/277 (89.5)6/69 (8.7)7/197 (3.6)16/212 (7.5)*EB* Enterobacteriaceae, *NA* not applicable (no intermediate zone), *PA Pseudomonas*

Direct AST for gram-negative bacilli -- period II {#Sec10}
-------------------------------------------------

During the second study period, direct AST was performed by both direct Phoenix and Alfred 60^AST^ on 85 Enterobacteriaceae and 6 *P. aeruginosa* with a CA of 92.2% (270/293) as detailed in Table [3](#Tab3){ref-type="table"}. No VME were observed. ME and mE rates were respectively 5.2% (13/251) and 4.3% (10/235). ME concerned cefuroxime, ceftazidime EB, piperacillin-tazobactam EB and ceftazidime PA respectively 2.2% (1/45), 12.2% (9/74), 3.6% (2/53) and 33.3% (1/3). Nearly optimal CA was observed for cefuroxime and ciprofloxacin with respectively 98.1% (51/52) and 97.7% (88/90) CA. Table 3AST results with Alfred 60^AST^ compared to direct Phoenix for Gram-negative bacteria during Period IIAntibioticCategorical agreement (%)Very major errors (%)Major errors (%)Minor errors (%)Cefuroxime^a^51/52 (98.1)0/71/45 (2.2)NACeftazidime EB68/84 (81)0/89/74 (12.2)7/84 (8.3)Piperacillin-tazobactam EB^a^58/61 (95.1)0/42/56 (3.6)1/61 (1.6)Ceftazidime PA5/6 (83.3)0/31/3 (33.3)NACiprofloxacin88/90 (97.7)0/160/732/90 (2.2)Total270/293 (92.2)0/38 (0)13/251 (5.2)10/235 (4.3)*EB* Enterobacteriaceae, *NA* not applicable (no intermediate zone), *PA Pseudomonas*^a^Modified antibiotic reagent

Direct AST for gram-positive cocci -- periods I&II {#Sec11}
--------------------------------------------------

Combining study periods I and II, direct AST was performed with both Alfred and Phoenix for 25 Enterococci, 45 coagulase-negative Staphylococci and 39 *S. aureus*. CA, VME, ME and mE were respectively 88.1% (96/109), 2.3% (1/44), 13.8% (9/65) and 12% (3/25) as presented in Table [4](#Tab4){ref-type="table"}. The single VME concerned an *E. faecium* erroneously ampicilline susceptible according to Alfred 60^AST^ results. ME mainly concerned cefoxitin coagulase negative Staphylococci with 8/19 ME. Cefoxitin *Staphylococcus aureus* performed optimally with a 100% CA for all 39 tested *S.aureus* strains. Table 4AST results with Alfred 60^AST^ compared to direct Phoenix for Gram-positive bacteria during both periodsAntibioticCategorical agreement (%)Very major errors (%)Major errors (%)Minor errors (%)Ampicillin Enterococci20/25 (80)1/15 (6.7)1/10 (10)3/25 (12)Cefoxitin CNS37/45 (82.2)0/268/19 (42.1)NACefoxitin SA39/39 (100)0/30/36NATotal96/109 (88.1)1/44 (2.3)9/65 (13.8)3/25 (12)*CNS* coagulase-negative Staphylococci, *NA* not applicable (No intermediate zone), *SA Staphylococcus aureus*

Turnaround time analysis {#Sec12}
------------------------

Median TAT to complete AST results with Alfred 60^AST^ was calculated at 4 h05 and 5 h55 including a sub-TAT of 1 h05 and 0 h55 to reach a 0.4--0.6 McFarland suspension for respectively Gram-positive and Gram-negative bacteria. Through the application of the workflow presented in Fig. [1](#Fig1){ref-type="fig"} all Alfred 60^AST^ results were accessible on the same day by 5 PM.

Direct phoenix results were reached after a median TAT of 12 h34 corresponding to 12 h27 for Gram-negative bacteria and 12 h41 for Gram-positive bacteria.

Discussion {#Sec13}
==========

Bacteremia is a worldwide cause of hospitalization and any kind of delay in appropriate antibiotherapy could be harmful or even fatal for the patient \[[@CR16]\]. The wait for both identification and AST results from positive blood cultures can lead to a broad spectrum or ineffective antibiotherapy and exposes the patient to the emergence of multi-resistant bacteria \[[@CR17]\], morbidity and mortality \[[@CR18], [@CR19]\]. Speeded-up positive blood culture testing is therefore an important challenge for the hospital microbiology laboratory. Many authors focused on rapid identification by MALDI-TOF MS directly on positive blood cultures \[[@CR7], [@CR20]\]. However, publications about direct AST methods are less prevalent and mainly address testing on AST automated systems. Beuving et al. evaluated direct inoculation of the Phoenix from positive blood cultures and showed a CA of 95.4% \[[@CR21]\]. Similarly Pan et al. performed Vitek AST on positive blood cultures resulting into a 96.9 and 92.8% CA for respectively Gram-negative and Gram-positive bacteria \[[@CR22]\]. At present many microbiology laboratories have introduced this direct AST approach in routine management of positive blood cultures subsequently reducing TAT to antimicrobial results with 24 h. Nonetheless results remain unavailable on the day of blood culture positivity detection. To this end, Alifax has developed an innovative AST approach based on light scattering measurements detecting the absence/presence of bacteria in a drug suspension within a few hours. In this study the Alfred 60^AST^ system and 8 selected antibiotics were challenged with 275 positive blood cultures and results were compared to those obtained with direct Phoenix testing in terms of microbiological performances and TAT. Alfred AST results for Gram-negative bacteria during period I showed moderate performances with a CA of 89.5% which is below the Cumitech acceptable performance rates \[[@CR15]\]. Other authors reported similar to slightly higher CA results ranging between 87.7 and 97.7% \[[@CR12], [@CR23], [@CR24]\]. In our study discrepancies were mainly associated with cefuroxime and piperacillin-tazobactam EB testing. Giordano et al. reported similar results for piperacillin-tazobactam EB with a CA for this antibiotic of 77.3% including 7 ME and 3 mE \[[@CR24]\]. Conversely, this team did not observe any errors concerning cefuroxime however only 4 strains were tested. The significant amount of VME and ME led the Alifax Company to review cefuroxime and piperacillin-tazobactam EB reagents and conducted into the delivery of new antibiotic formulations. Subsequently an additional evaluation was performed on Gram-negative bacteria (Period II) with the absence of VME for both antibiotics and an improved global CA of 92.2% considered as adequate according to the Cumitech acceptable performance rates \[[@CR15]\]. Ultimately remaining ME and mE were majorly linked to ceftazidime EB results. Our first hypothesis that errors might have been linked to the variable expression of an ESBL enzyme was countered as only 3/15 mE and 0/11 ME were associated with ESBL strains. We therefore suppose the Alfred 60^AST^ ceftazidime EB antibiotic was too weakly concentrated leading to false resistance results. Nevertheless cefotaxime is globally more sensitive for the detection of ESBL producers and should be included in the Gram-negative Alfred 60^AST^ panel when applied in routine to avoid clinical failure with third generation cephalosporins particularly for CTX-M producing Enterobacteriaceae that are cefotaxime resistant but ceftazidime susceptible. Despite only 2 ME concerning ceftazidime PA and a complete concordance concerning ciprofloxacin, AST results for *P. aeruginosa* strains are of little value as only 11 strains could be evaluated. Barnini et al. who similarly studied a population of 12 *P. aeruginosa* strains on Alfred 60^AST^ showed a total CA of 89.3% for amikacin, colistin, gentamicin, levofloxacin yet ceftazidime PA was not tested \[[@CR23]\]. CA for AST on Gram-positive bacteria with Alfred 60^AST^ was 88.1% essentially due to a ME rate as high as 42% for cefoxitin tested on coagulase-negative Staphylococci and hereby not meeting the Cumitech acceptable performance rates \[[@CR15]\]. Other authors obtained a Gram-positive CA between 85.1 and 93.7% \[[@CR23], [@CR24]\]. Similarly Barnini et al. reported cefoxitin ME rates for Staphylococci of 14.3 and 17.2% with 2 Alfred 60^AST^ test protocols \[[@CR23]\]. Inadequately suppressing the antibiotic option of a small spectrum beta-lactam due to erroneous cefoxitin resistance detection could lead to the excess use of broad-spectrum antibiotics including vancomycin. Therefore we believe a review of the composition of the cefoxitin antibiotic for coagulase-negative Staphylococci should be considered. Finally considering the *S. aureus* population, cefoxitin showed an optimal CA as observed by others \[[@CR24]\]. This is of importance, mainly because the rapid detection of a blood infection by a methicillin-resistant *S. aureus* requires the rapid instauration of a broad-spectrum antibiotherapy \[[@CR25]\].

A major asset of AST testing with Alfred 60^AST^ is TAT to results calculated in our study at 4 h05 for Gram-positive bacteria and 5 h55 for Gram-negative bacteria. With this approach all positive blood cultures detected in the morning have a susceptibility profile by the end of the same day which can be considered as a drastic improvement compared with classical subculture AST testing but also compared with direct automated testing used as reference AST technique in our study. The calculated TAT of the Alfred 60^AST^ approach is quite similar to the TAT of the rapid AST technique recently introduced by EUCAST based on disk diffusion directly from positive blood cultures and interpretation of inhibition zones according to specific breakpoints after 4, 6 or 8 h. To her advantage the latter technique does not require any automated system or specific reagents however current published breakpoints are available for a limited amount of antibiotics and only 7 strains (*E. coli*, *K. pneumoniae*, *P. aeruginosa*, *E. faecalis* and *faecium*, *S. aureus* and *S. pneumoniae*). In our study the application of the EUCAST rapid AST approach would have limited the availability of AST results to 79% of the Gram-negative strains and 58.7% of the Gram-positive strains.

Our study included some drawbacks. At first our positive blood culture collection was low in multi-resistant strains and additional testing needs to be performed on methicillin-resistant *S. aureus*, ESBL and carbapenemase-producing Enterobacteriaceae as well as multi-resistant *P. aeruginosa* for a more accurate evaluation of VME rates. Alongside our evaluation of Alfred 60^AST^ was restricted to a limited panel of antibiotics chosen in accordance with our local resistance epidemiology. In a setting with high prevalence rates of multi-resistant bacteria, meropenem and vancomycin must be part of the customized antibiotic panels. Finally caution is required when global CA, VME, ME and mE are compared between publications as every team evaluates distinct antibiotic panels with different strains including varying resistance profiles.

The phase following this microbiological performances evaluation would be the introduction of Alfred 60^AST^ testing in the routine management of positive blood cultures with the assessment of the impact on patient's outcome. A retrospective cohort study of Menon et al. concluded to a speeded-up antibiotic change in 28% of bacteremia cases through the use of susceptibility testing with disk diffusion directly from positive blood cultures versus testing on subcultured colonies \[[@CR26]\]. In an interventional study, Verroken et al. similarly calculated a time gain of 18.2 h towards optimal antimicrobial treatment with the introduction of a speeded-up positive blood culture workflow including direct MALDI-TOF MS identification, rapid resistance detection testing and direct automated AST \[[@CR27]\]. We believe the routine integration of Alfred 60^AST^ testing as suggested in Fig. [1](#Fig1){ref-type="fig"} would allow analogous observations with an even shorter TAT towards antibiotic tailoring and a potential impact on patient's mortality and length of stay. However it is important to recall that in our study Alfred 60^AST^ testing was limited to positive blood cultures detected positive until 10 AM. Extending the inclusion time frame would concurrently set back the time to available results towards evening/night hours requiring an around-the-clock running laboratory and the full-time accessibility of the clinician in charge of the concerned patient to perform instant antibiotic tailoring.

Conclusion {#Sec14}
==========

Alfred 60^AST^ is an automated instrument based on light scattering technology aimed to perform antimicrobial susceptibility directly on positive blood cultures. Our evaluation shows moderate to acceptable microbiological performances and a major TAT reduction compared to current routine AST approaches. Additional optimization of certain antibiotics reagents would be an asset and improve AST results. In the near future the clinical outcome of this approach should be investigated for a rapid and effective antibiotic management of patients with bacteremia.
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